Pomerantz LLP is investigating Alibaba Group for potential securities fraud and unlawful business practices following reports that Alibaba illicitly accessed AI technology and failed to prevent illegal pharmaceutical sales on its platform. These allegations caused Alibaba's ADR price to drop significantly. The U.S. Department of Justice also announced a $600 million non-prosecution agreement with Alibaba related to the sale of illegal drugs through its e-commerce sites. Investors affected by these issues are encouraged to contact Pomerantz LLP for potential class action involvement.
China's regulator has approved Apple Intelligence, Apple's generative AI service, for launch in China through a partnership integrating Alibaba's Qwen AI model into Apple’s operating systems. This collaboration enables AI features like text and image...
Alibaba confirmed that its Qwen AI model will be integrated into Apple's iOS, iPadOS, macOS, and visionOS services for users in China, leading to a 4% rise in its U.S.-listed shares in premarket trading. This integration allows users to access advanc...
Last week, leveraged ETFs linked to Alibaba, Meta, Broadcom, and Nvidia delivered strong gains ranging from 17% to over 34%. Alibaba-focused ETFs led with over 34% returns, driven by positive earnings previews, AI revenue growth, and share buybacks. ...
In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...
US AI companies Anthropic and OpenAI have accused Chinese firms, including Alibaba, of illegally copying advanced AI technology through a method called "distillation," which allows cheaper and faster AI model development. This practice threatens US d...
